Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma

C.M.J. Steendam, R. Peric, N.C. van Walree, M. Youssef, F.M.N.H. Schramel, P. Brocken, J.W.G. van Putten, V. van der Noort, G.D.M. Veerman, S.L.W. Koolen, H.J.M. Groen, A.M.C. Dingemans, R.H.J. Mathijssen, E.F. Smit, J.G.J.V. Aerts*, NVALT Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma'. Together they form a unique fingerprint.

INIS

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science